Fluocinolone acetonide intravitreal implant reduces macular edema through 36 months

A fluocinolone acetonide intravitreal implant (Fai) (Yutiq; EyePoint Pharmaceuticals) insert reduced rates of macular edema and improved visual acuity in eyes with noninfectious uveitis affecting the posterior segment (NIU-PS) through 36 months, according to a presentation at the 2020 ASRS Virtual Meeting.

In this prospective, randomized, phase 3 clinical trial, patients with chronic NIU-PS who had experienced at least 2 recurrences requiring ≥3 months of systemic therapy or ≥2 intra- or periocular steroid injections, were randomized to receive an FAi (n = 87) or sham injection (n = 42).

At baseline, 58.6% of eyes in the Fai group and 66.7% of eyes in the sham-treated group had macular edema. At 36 months that decreased to 10.3% of eyes in the Fai group and 21.4% of eyes in the sham-treated group.

At 6 months, median decreases from baseline for central foveal thickness, central subfield thickness, and total volume of central subfield were greater in the FAi group than the sham group but similar at 36 months.

Reference
Hariprasad SM, et al. Course of macular edema through 36 months with fluocinolone acetonide intravitreal insert for non-infectious uveitis affecting the posterior segment. Presented at: 2020 ASRS Virtual Meeting